definiens: means a DIAGNOSTIC PRODUCT or PHARMACEUTICAL PRODUCT wherein the LICENSED MONOBODY comprising that PRODUCT has been identified, isolated or discovered through the use of ADNEXUS TECHNOLOGY . ” 1.18 . means the [ * * ] molecules are generated with a [ * * ] and wherein peptides or proteins having a desired binding affinity are [ * * ] . The ADNEXUS TECHNOLOGY, including a description of [ * * ], is described and [ * * ] . ” SECTION 2.2 . Paragraph 3.3 of the Agreement is amended by deleting it in its entirety and replacing it with the following : 3.3 . Licensee may enter into arrangements with a commercial partner, not an AFFILIATE, to develop and/or comm ercialize PHYLOS PRODUCTS ( a ) . In connection with that development and/or commercialization effort, Licensee may desire that the Qualified Licensee Prospect have the right to research, develop, make, market and SELL PHYLOS PRO DUCTS . From time to time, Licensee may provide to RCT a written request that RCT grant a license under the LICENSED PATENTS to a Qualified Licensee Prospect . Promptly after receiving such written request, RCT shall offer to the Qualified Licensee Prospect identified in Licensee ’s written notice a license under the LICENSED PATENTS to research, develop, make, USE, SELL, offer to SELL and import PHYLOS PRODUCTS at the [ * * ] and the other terms of which will be substantially in the form of Exhibit B to this Agr eement . [ * * ] . For the avoidance of doubt, [ * * ] . For purposes of clarity, a Qualified Licensee Prospect is a RELATED PARTY of Licensee under this Agreement . ” SECTION 2.3 . Article 10 of the Agreement is hereby amended by changing the first line thereof to read as follows : This Agreement ( and any exhibits attached to this Agreement ), as amended by that certain Amendment No